LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

19.82 -5.62

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.85

Max

20.89

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -50M
Pardavimai	12M 128M
Pelno marža	-39.506
Darbuotojai	1,784
EBITDA	-17M -48M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+67.87% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	174M 2.4B
Ankstesnė atidarymo kaina	25.44
Ankstesnė uždarymo kaina	19.82

Naujienos nuotaikos

By Acuity

43%

57%

141 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

28.13 / 31.12 Palaikymas ir pasipriešinimas

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-07 23:58; UTC

Uždarbis

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026-05-07 22:57; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026-05-07 23:52; UTC

Uždarbis

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026-05-07 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-05-07 23:39; UTC

Rinkos pokalbiai

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026-05-07 23:28; UTC

Rinkos pokalbiai

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026-05-07 23:11; UTC

Uždarbis

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026-05-07 23:06; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026-05-07 23:05; UTC

Uždarbis

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026-05-07 23:04; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026-05-07 23:03; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026-05-07 23:02; UTC

Uždarbis

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026-05-07 23:00; UTC

Rinkos pokalbiai

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-07 22:45; UTC

Rinkos pokalbiai

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026-05-07 22:42; UTC

Uždarbis

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026-05-07 22:33; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026-05-07 22:32; UTC

Uždarbis

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026-05-07 22:31; UTC

Uždarbis

Macquarie: 68% of FY Income From International >MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026-05-07 22:30; UTC

Uždarbis

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026-05-07 22:29; UTC

Uždarbis

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026-05-07 22:28; UTC

Uždarbis

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026-05-07 22:27; UTC

Uždarbis

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026-05-07 22:26; UTC

Uždarbis

Macquarie to End Share Buyback Extended in November>MQG.AU

2026-05-07 22:25; UTC

Uždarbis

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

67.87% į viršų

12 mėnesių prognozė

Vidutinis 35.27 USD 67.87%

Aukščiausias 47 USD

Žemiausias 21.8 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

28.13 / 31.12Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

Rinkos nuotaikos

By Acuity

141 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.